2017 Amyotrophic Lateral Sclerosis Pipeline Highlights Update - ResearchAndMarkets.com

DUBLIN--()--The "Amyotrophic Lateral Sclerosis Pipeline Highlights - 2017 Update" drug pipelines has been added to ResearchAndMarkets.com's offering.

Amyotrophic Lateral Sclerosis Pipeline Highlights - 2017 Update, provides most up-to-date information on key pipeline products in the global Amyotrophic Lateral Sclerosis market.

It covers emerging therapies for Amyotrophic Lateral Sclerosis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Amyotrophic Lateral Sclerosis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Amyotrophic Lateral Sclerosis pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Amyotrophic Lateral Sclerosis pipeline products by the company.

Short-term Launch Highlights:

Find out which Amyotrophic Lateral Sclerosis pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Amyotrophic Lateral Sclerosis Pipeline by Stages

2. Amyotrophic Lateral Sclerosis Pipeline by Drug Class

3. Amyotrophic Lateral Sclerosis Pipeline by Company

4. Amyotrophic Lateral Sclerosis Phase 3 Clinical Trial Insights

5. Amyotrophic Lateral Sclerosis Phase 2 Clinical Trial Insights

6. Amyotrophic Lateral Sclerosis Phase 1 Clinical Trial Insights

7. Amyotrophic Lateral Sclerosis Preclinical Research Insights

8. Amyotrophic Lateral Sclerosis Discovery Stage Insights

9. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5s7q8n/2017_amyotrophic?w=4.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs